- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 127043, 10 pages
Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin
1School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan
2School of Pharmacy, Taipei Medical University, Taipei 100, Taiwan
3Department of Internal Medicine, Hospital and College of Medicine, National Taiwan University, Taipei 100, Taiwan
Received 29 May 2012; Revised 13 September 2012; Accepted 3 October 2012
Academic Editor: Alfredo Vannacci
Copyright © 2012 Chia-Hao Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. Lewington, G. Whitlock, R. Clarke, et al., “Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths,” The Lancet, vol. 370, no. 9602, pp. 1829–1839, 2007.
- D. Heber, I. Yip, J. M. Ashley, D. A. Elashoff, R. M. Elashoff, and V. L. W. Go, “Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement,” American Journal of Clinical Nutrition, vol. 69, no. 2, pp. 231–236, 1999.
- C. C. Lin, T. C. Li, and M. M. Lai, “Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia,” European Journal of Endocrinology, vol. 153, no. 5, pp. 679–686, 2005.
- J. Liu, J. Zhang, Y. Shi, S. Grimsgaard, T. Alraek, and V. Fønnebø, “Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials,” Chinese Medicine, vol. 1, article 4, 2006.
- C. F. Huang, T. C. Li, C. C. Lin, C. S. Liu, H. C. Shih, and M. M. Lai, “Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 14, no. 3, pp. 438–440, 2007.
- S. P. Zhao, Z. L. Lu, B. M. Du et al., “Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China Coronary Secondary Prevention Study (CCSPS),” Journal of Cardiovascular Pharmacology, vol. 49, no. 2, pp. 81–84, 2007.
- Z. Lu, W. Kou, B. Du et al., “Effect of xuezhikang, an extract from red yeast Chinese rice, on coronary events in a chinese population with previous myocardial infarction,” American Journal of Cardiology, vol. 101, no. 12, pp. 1689–1693, 2008.
- M. Klimek, S. Wang, and A. Ogunkanmi, “Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia,” P and T, vol. 34, no. 6, pp. 313–327, 2009.
- Q. Shang, Z. Liu, K. Chen, H. Xu, and J. Liu, “A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 636547, 18 pages, 2012.
- D. J. Becker, R. Y. Gordon, P. B. Morris et al., “Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial,” Mayo Clinic Proceedings, vol. 83, no. 7, pp. 758–764, 2008.
- D. J. Becker, R. Y. Gordon, S. C. Halbert, B. French, P. B. Morris, and D. J. Rader, “Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial,” Annals of Internal Medicine, vol. 150, no. 12, pp. 830–839, 2009.
- R. Y. Gordon, T. Cooperman, W. Obermeyer, and D. J. Becker, “Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!,” Archives of Internal Medicine, vol. 170, no. 19, pp. 1722–1727, 2010.
- A. W. Alberts, J. Chen, G. Kuron, et al., “Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 7, pp. 3957–3961, 1980.
- R. W. Wang, P. H. Kari, A. Y. H. Lu, P. E. Thomas, F. P. Guengerich, and K. P. Vyas, “Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes,” Archives of Biochemistry and Biophysics, vol. 290, no. 2, pp. 355–361, 1991.
- C. Chen, R. J. Mireles, S. D. Campbell et al., “Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1,” Drug Metabolism and Disposition, vol. 33, no. 4, pp. 537–546, 2005.
- S. C. Halbert, B. French, R. Y. Gordon et al., “Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance,” American Journal of Cardiology, vol. 105, no. 2, pp. 198–204, 2010.
- C. V. Venero, J. V. Venero, D. C. Wortham, and P. D. Thompson, “Lipid-lowering efficacy of red yeast rice in a population intolerant to statins,” American Journal of Cardiology, vol. 105, no. 5, pp. 664–666, 2010.
- G. V. R. Prasad, T. Wong, G. Meliton, and S. Bhaloo, “Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient,” Transplantation, vol. 74, no. 8, pp. 1200–1201, 2002.
- D. J. Smith and K. E. Olive, “Chinese red rice-induced myopathy,” Southern Medical Journal, vol. 96, no. 12, pp. 1265–1267, 2003.
- P. S. Mueller, “Symptomatic myopathy due to red yeast rice,” Annals of Internal Medicine, vol. 145, no. 6, pp. 474–475, 2006.
- H. Roselle, A. Ekatan, J. Tzeng, M. Sapienza, and J. Kocher, “Symptomatic hepatitis associated with the use of herbal red yeast rice,” Annals of Internal Medicine, vol. 149, no. 7, pp. 516–517, 2008.
- R. J. Stubbs, M. Schwartz, and W. F. Bayne, “Determination of mevinolin and mevinolinic acid in plasma and bile by reversed-phase high-performance liquid chromatography,” Journal of Chromatography, vol. 383, no. 2, pp. 438–443, 1986.
- R. L. Walsky and R. S. Obach, “Validated assays for human cytochrome P450 activities,” Drug Metabolism and Disposition, vol. 32, no. 6, pp. 647–660, 2004.
- M. Yao, M. Zhu, M. W. Sinz et al., “Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis,” Journal of Pharmaceutical and Biomedical Analysis, vol. 44, no. 1, pp. 211–223, 2007.
- J. Rautio, J. E. Humphreys, L. O. Webster et al., “In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates,” Drug Metabolism and Disposition, vol. 34, no. 5, pp. 786–792, 2006.
- C. H. Chen, H. J. Hsu, Y. J. Huang, and C. J. Lin, “Interaction of flavonoids and intestinal facilitated glucose transporters,” Planta Medica, vol. 73, no. 4, pp. 348–354, 2007.
- Y. Ohno, A. Hisaka, and H. Suzuki, “General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs,” Clinical Pharmacokinetics, vol. 46, no. 8, pp. 681–696, 2007.
- M. Cesari and A. C. Pessina, “Combined antihypertensive and lipid-Lowering treatment,” Current Hypertension Reports, vol. 6, no. 4, pp. 300–306, 2004.
- C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila, and P. J. Neuvonen, “Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate,” Clinical Pharmacology and Therapeutics, vol. 69, no. 5, pp. 340–345, 2001.
- P. J. Neuvonen, M. Niemi, and J. T. Backman, “Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance,” Clinical Pharmacology and Therapeutics, vol. 80, no. 6, pp. 565–581, 2006.
- P. J. Neuvonen, J. T. Backman, and M. Niemi, “Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin,” Clinical Pharmacokinetics, vol. 47, no. 7, pp. 463–474, 2008.
- T. D. Bjornsson, J. T. Callaghan, H. J. Einolf et al., “The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective,” Journal of Clinical Pharmacology, vol. 43, no. 5, pp. 443–469, 2003.
- L. Zhang, Y. Zhang, J. M. Strong, K. S. Reynolds, and S. M. Huang, “A regulatory viewpoint on transporter-based drug interactions,” Xenobiotica, vol. 38, no. 7-8, pp. 709–724, 2008.
- US Food and Drug Administration, Guidance for industry on drug interaction studies- study design, data analysis, implications for dosing, and labeling recommendations, 2012, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
- I. Os, B. Bratland, B. Dahlof, K. Gisholt, J. O. Syvertsen, and S. Tretli, “Effect and tolerability of combining lovastatin with nifedipine or lisinopril,” American Journal of Hypertension, vol. 6, no. 8, pp. 688–692, 1993.
- K. S. Fenner, M. D. Troutman, S. Kempshall et al., “Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug,” Clinical Pharmacology and Therapeutics, vol. 85, no. 2, pp. 173–181, 2009.
- S. Agarwal, V. Arya, and L. Zhang, “Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed [I1]/IC50 and [I2]/IC50 criteria in the P-gp decision tree,” The Journal of Clinical Pharmacology. In press.
- M. A. Omar and J. P. Wilson, “FDA adverse event reports on statin-associated rhabdomyolysis,” Annals of Pharmacotherapy, vol. 36, no. 2, pp. 288–295, 2002.
- T. Prueksaritanont, B. Ma, and N. Yu, “The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6,” British Journal of Clinical Pharmacology, vol. 56, no. 1, pp. 120–124, 2003.
- Y. Shitara, M. Hirano, H. Sato, and Y. Sugiyama, “Gemfibrozil and its glucoronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil,” Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 1, pp. 228–236, 2004.
- U. Fuhr, H. Müller-Peltzer, R. Kern et al., “Effects of grapefruit juice and smoking on verapamil concentrations in steady state,” European Journal of Clinical Pharmacology, vol. 58, no. 1, pp. 45–53, 2002.
- M. Kazui, Y. Nishiya, T. Ishizuka et al., “Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite,” Drug Metabolism and Disposition, vol. 38, no. 1, pp. 92–99, 2010.
- C. H. Chen, J. C. Yang, Y. S. Uang, and C. J. Lin, “Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel,” Biopharmaceutics & Drug Disposition, vol. 33, no. 5, pp. 278–283, 2012.
- J. L. Mega, S. L. Close, S. D. Wiviott et al., “Cytochrome P-450 polymorphisms and response to clopidogrel,” New England Journal of Medicine, vol. 360, no. 4, pp. 354–362, 2009.
- J. C. Yang and C. J. Lin, “CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection,” Expert Opinion on Drug Metabolism and Toxicology, vol. 6, no. 1, pp. 29–41, 2010.